Alkermes Plc (ALKS) Director Paul J. Mitchell Sells 1,000 Shares

Alkermes Plc (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $54.99, for a total value of $54,990.00. Following the completion of the transaction, the director now owns 9,000 shares in the company, valued at approximately $494,910. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Alkermes Plc (ALKS) traded down $1.45 during midday trading on Thursday, hitting $54.44. The company had a trading volume of 727,463 shares, compared to its average volume of 933,788. The company has a market cap of $8,370.00, a PE ratio of -49.05 and a beta of 2.13. Alkermes Plc has a 1-year low of $46.42 and a 1-year high of $63.40. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. The business had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.09) EPS. analysts predict that Alkermes Plc will post -0.59 EPS for the current fiscal year.

A number of equities analysts have recently weighed in on the company. Barclays set a $50.00 target price on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. ValuEngine downgraded Alkermes from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. set a $78.00 target price on Alkermes and gave the company a “buy” rating in a report on Friday, October 27th. BidaskClub upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Finally, Citigroup set a $62.00 target price on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $63.55.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Toronto Dominion Bank grew its stake in shares of Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Alkermes in the 3rd quarter valued at approximately $126,000. Virtu Financial LLC bought a new stake in shares of Alkermes in the 3rd quarter valued at approximately $201,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Alkermes in the 3rd quarter valued at approximately $214,000. Finally, Trexquant Investment LP bought a new stake in shares of Alkermes in the 3rd quarter valued at approximately $218,000. 99.17% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3125712/alkermes-plc-alks-director-paul-j-mitchell-sells-1000-shares-2.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.